By a News Reporter-Staff News Editor at Physician Law Weekly -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting originating in Portland, Oregon, by NewsRx journalists, research stated, “The ProtecT trial provides Level 1 evidence supporting active surveillance for low-risk and intermediate-risk prostate cancer. The impact of these findings on the opinions of North American genitourinary oncology expert radiation oncologists regarding the role of active surveillance was investigated; active surveillance is well-regarded for low-risk but not intermediate-risk prostate cancer.”
The news reporters obtained a quote from the research from Oregon Health and Science University, “These preferences may affect the design of future clinical studies, influencing the adoption of active surveillance in North American clinical practice. The ProtecT trial has provided level 1 evidence supporting active surveillance for prostate cancer patients with low-risk and intermediate-risk disease. The effect of these findings on the opinions of North American genitourinary (GU) experts regarding the role of active surveillance for these patients has not been previously examined. A survey was distributed to 88 practicing North American GU physicians serving on decision-making committees of cooperative group research organizations. Questions pertained to appropriateness of active surveillance in patients with low-risk and intermediate-risk (Gleason 3+4) disease. Opinions regarding active surveillance were correlated with practice patterns using Fisher exact test. Forty-two radiation oncologists completed the survey. Forty percent had been in practice for more than 20 years; 90% practice at an academic center. Forty-five percent see >= 20 patients per month in consultation. More than 95% (40 of 42) recommended active surveillance for Gleason 6 disease, whereas only 17% recommended active surveillance for Gleason 3+4 disease. There were no demographic differences between supporters or opponents regarding active surveillance with regard to monthly patient volume, practice type, likelihood of self-identifying as an expert brachytherapist, belief in advanced imaging techniques, or preferred default external beam radiation therapy dose/fractionation for either low-risk or intermediate-risk disease. However, there was a trend toward greater support of active surveillance for Gleason 3+4 disease among experts having practiced <10 years versus >= 10 years (P=.085). Active surveillance is almost universally supported by North American GU expert radiation oncologists for low-risk prostate cancer. However, there is very weak support for this strategy in Gleason 3+4 disease despite the ProtecT trial providing level 1 evidentiary support in both risk groups. There were no significant differences between experts supporting versus opposing active surveillance for either low-risk or intermediate-risk disease.”
According to the news reporters, the research concluded: “These preferences might affect the design of future clinical studies, influencing the adoption of active surveillance in North American clinical practice.”
For more information on this research see: Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists. Clinical Genitourinary Cancer , 2018;16(2):E323-E325. Clinical Genitourinary Cancer can be contacted at: Cig Media Group, Lp, 3500 Maple Avenue, Ste 750, Dallas, TX 75219-3931, USA. (Elsevier - www.elsevier.com; Clinical Genitourinary Cancer - http://www.journals.elsevier.com/clinical-genitourinary-cancer/)
Our news correspondents report that additional information may be obtained by contacting T. Mitin, Oregon Health Sciences University, Dept. of Radiat Med, Portland, OR 97239, United States. Additional authors for this research include K.A. Sandler, C. Degnin, Y.Y. Chen and S. McClelland.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.clgc.2017.10.021. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-05-02), Studies from Oregon Health and Science University in the Area of Prostate Cancer Reported (Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists), Physician Law Weekly, 481, ISSN: 1551-5303, BUTTER® ID: 015569823
From the newsletter Physician Law Weekly.
https://www.newsrx.com/Butter/#!Search:a=15569823
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.